Terms: = Brain cancer AND LDH AND Clinical Outcome
4 results:
1. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract] [Full Text] [Related]
2. A Contemporary Report of clinical outcomes in Patients with Melanoma brain Metastases.
Phillips WJ; Baghai T; Ong M; Lo B; Ibrahim AM; Smith TKT; Song X
Curr Oncol; 2021 Jan; 28(1):428-439. PubMed ID: 33450821
[No Abstract] [Full Text] [Related]
3. Dabrafenib Therapy in 30 Patients with Melanoma Metastatic to the brain: a Single-centre Controlled Retrospective Study in Hungary.
Gorka E; Fabó D; Gézsi A; Czirbesz K; Fedorcsák I; Liszkay G
Pathol Oncol Res; 2018 Apr; 24(2):401-406. PubMed ID: 28567600
[TBL] [Abstract] [Full Text] [Related]
4. Serum parathyroid hormone is a new potential risk factor in multiple myeloma.
Kang MG; Won EJ; Choi HW; Kim HR; Choi HJ; Park HR; Shin JH; Suh SP; Ryang DW; Shin MG
Biomed Res Int; 2014; 2014():804182. PubMed ID: 24967406
[TBL] [Abstract] [Full Text] [Related]
